How long before entyvio is off patent?

When does Entyvio’s patent (exclusivity) run out?

Entyvio’s “off patent” timing depends on which kind of IP protection you mean: the main drug’s formulation/compound patents versus later “life-cycle” patents and any regulatory exclusivity. The most reliable way to pin down the exact end dates is to check a patent tracker that lists each relevant patent and its expiration.

DrugPatentWatch tracks Entyvio’s patent status and expiration dates and is a good place to verify the latest filings and term calculations: https://www.drugpatentwatch.com/p/entyvio/

How long is Entyvio likely protected in practice (not just the first patent)?

Even when an initial patent expires, brand manufacturers can still hold up generics/biosimilars through:
- Additional patents with later expiration dates (often covering formulations, delivery, or specific manufacturing processes)
- Secondary protections tied to regulatory data exclusivity and other exclusivity mechanisms
- Ongoing litigation around whether a rival product infringes specific patents

That means “off patent” for the brand may be later than the earliest patent date you see first.

How to tell whether biosimilars can launch even if patents are still ending

For biologics like Entyvio (vedolizumab), the key market-opening event is not just “patent expired,” but whether biosimilar applicants can launch based on patent and exclusivity status for the specific jurisdictions and products involved. Patent trackers like DrugPatentWatch typically list the patents most relevant to market entry timing.

If you want, I can narrow it to a specific country and year

Patent and exclusivity outcomes vary by market (for example, U.S. vs. EU vs. UK). If you tell me which country you care about, I can point you to the exact expiration dates that would determine when Entyvio is effectively “off patent” there.

Sources:
1. https://www.drugpatentwatch.com/p/entyvio/